Rathmann's model for Japan partnering

Most biotechnology companies thinking about a Japanese partner are doing it for the market access. Not many are thinking about a true development partner, and even fewer are thinking about joint ventures. But George Rathmann, Icos Corp. chairman, president and CEO, has taken the joint venture route twice with Japanese pharmaceutical companies. The first time was with Kirin Brewery Co. Ltd. of Tokyo when he was CEO of Amgen Inc.

This time, ICOS has put together a joint venture with Suntory Ltd.'s Suntory Pharmaceutical Division

Read the full 841 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE